{"id":46055,"date":"2022-07-12T11:02:08","date_gmt":"2022-07-12T09:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/"},"modified":"2022-07-12T11:02:08","modified_gmt":"2022-07-12T09:02:08","slug":"spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/","title":{"rendered":"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer"},"content":{"rendered":"
\n

\nNovel Vaccine Company Expands Leadership Team and Establishes US Presence<\/i>\n<\/p>\n

OXFORD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company\u2019s co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts.\n<\/p>\n

<\/a><\/p>\n

\nMark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO of Brooklyn ImmunoTherapeutics and Chairman, President and CEO of IRX Therapeutics. He has over 20 years of experience as a CEO in the biopharmaceutical industry and has led companies through private financings and initial public offerings, taken products from research to IND and through to commercialization, and achieved M&A exits. Leuchtenberger was President and Chief Executive Officer and a member of the Board of Directors at Chiasma (NASDAQ: CHMA), Acusphere, Inc., Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics, Inc.), Targanta Therapeutics Corporation and Therion Biologics Corporation. Prior to Therion, he was a senior officer at Biogen Inc., where he led the late-stage development of the company\u2019s flagship product Avonex and its commercialization in North America and internationally in 65 countries. He is a director and past chairman of the Massachusetts Biotechnology Council Board of Directors, was a co-founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc., and currently serves as Chairman of the Board for Neurosense Therapeutics (NASDAQ: NRSN). He received his MBA from the Yale School of Management and his BA from Wake Forest University.\n<\/p>\n

\n\u201cIt is an honor to join the team at SpyBiotech as it advances its first proprietary SpyTag\/SpyCatcher protein superglue enabled VLP-based vaccine candidate into clinical trials,\u201d said Mark Leuchtenberger. \u201cWe have great ambition to utilize the benefits of our unique platform across various applications to address major human health challenges around the world.\u201d\n<\/p>\n

\nBased on science developed at the University of Oxford, SpyBiotech\u2019s novel vaccine platform is based on a proprietary protein \u201csuperglue\u201d technology which binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The technology is potentially one of the safest and most effective ways to create vaccines: cost-effective and highly scalable. This makes it ideal for use against infectious diseases in challenging environments, such as in the developing world, but also with potential application in non-infectious disease settings such as cancer. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialize and sub-license the SpyTag\/SpyCatcher technology and related technologies in vaccine development. The company\u2019s lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for 2023. The company sees a range of development opportunities in infectious diseases, cancer and beyond.\n<\/p>\n

\nSumi Biswas co-founded SpyBiotech in March 2017 and has been the company\u2019s CEO and CSO since inception. She has led scientific and strategic development during this period. With this expansion, Biswas continues as President and CSO.\n<\/p>\n

\n\u201cWhen we founded SpyBiotech, we envisioned building a commercial company centered on our unique technology platform that enables us to circumvent the challenges of binding antigens to virus-like particles and other vaccine delivery platforms,\u201d said Biswas. \u201cWith this visionary leadership team, SpyBiotech will continue to develop our technology along innovative pathways to prevent serious disease.\u201d\n<\/p>\n

\n\u201cAs we progress toward the clinic and expand upon our technology, Mark\u2019s deep expertise will be invaluable,\u201d said Board Chair Lutz B. Giebel, Ph.D. \u201cSpyBiotech stands at the forefront of vaccine innovation. Our expanded leadership team and footprint in the United States demonstrate strong progress as we continue to scale up our company.\u201d\n<\/p>\n

\nLast year the company announced $32.5 million in a Series A equity financing. Under Leuchtenberger\u2019s leadership, SpyBiotech intends to advance clinical development of its internal lead candidate, targeting human cytomegalovirus (HCMV), using its novel vaccine technology platform based on its proprietary SpyTag\/SpyCatcher protein \u201csuperglue\u201d technology.\n<\/p>\n

\nAbout SpyBiotech<\/b>\n<\/p>\n

\nSpyBiotech is a biotechnology company with a novel vaccine platform technology to target infectious diseases, cancer and chronic diseases. The company was spun out of the University of Oxford in 2017 by Oxford Science Enterprises (OSE) and has raised $39mm to date. Based on science developed at Oxford, SpyBiotech\u2019s novel vaccine platform is based on a proprietary protein \u201csuperglue\u201d technology which binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The technology is potentially one of the safest and most effective ways to create vaccines: cost-effective and highly scalable. This makes it ideal for use against infectious diseases in challenging environments, such as in the developing world, but also with potential application in non-infectious disease settings such as cancer. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialize and sub-license the SpyTag\/SpyCatcher technology in vaccine development. www.spybiotech.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Michael Falcone
\n
MacDougall Advisors
\n
781-235-3060
\n
mfalcone@macdougall.bio<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Novel Vaccine Company Expands Leadership Team and Establishes US Presence OXFORD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46055","6":"format-standard","7":"category-industry"},"yoast_head":"\nSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Novel Vaccine Company Expands Leadership Team and Establishes US Presence OXFORD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-12T09:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220712005230\/en\/1509947\/21\/SpyBiotech_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer\",\"datePublished\":\"2022-07-12T09:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/\"},\"wordCount\":848,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005230\\\/en\\\/1509947\\\/21\\\/SpyBiotech_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/\",\"name\":\"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005230\\\/en\\\/1509947\\\/21\\\/SpyBiotech_Logo.jpg\",\"datePublished\":\"2022-07-12T09:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005230\\\/en\\\/1509947\\\/21\\\/SpyBiotech_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005230\\\/en\\\/1509947\\\/21\\\/SpyBiotech_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Pharma Trend","og_description":"Novel Vaccine Company Expands Leadership Team and Establishes US Presence OXFORD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-12T09:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220712005230\/en\/1509947\/21\/SpyBiotech_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer","datePublished":"2022-07-12T09:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/"},"wordCount":848,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220712005230\/en\/1509947\/21\/SpyBiotech_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/","url":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/","name":"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220712005230\/en\/1509947\/21\/SpyBiotech_Logo.jpg","datePublished":"2022-07-12T09:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220712005230\/en\/1509947\/21\/SpyBiotech_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220712005230\/en\/1509947\/21\/SpyBiotech_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/spybiotech-appoints-seasoned-biotech-executive-mark-leuchtenberger-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46055"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46055\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}